Figure 5 | Scientific Reports

Figure 5

From: Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression

Figure 5

Cetuximab treatment alters protein expression and affects PLCB3 promoter activity associated with Wnt/β-catenin signaling in CRC cells. (A) The protein expression levels of β-catenin, Ecadherin and PCLB in Caco-2 and SW48 cells were detected by WB after cetuximab treatment. Different gels were used, and blots were combined for presentation, with clear delineations between them. (B) Schematic representation of two predicted TCF/LEF binding sites in the PLCB3 promoter region. (C–F) Dual-luciferase assays to assess PLCB3 promoter activity in Caco-2 and SW48 cells under various conditions: (C) Wnt inhibitor (21H7) treatment, (D) Wnt activator (IM12) treatment, (E, F) Cetuximab combined with 21H7 or IM12 treatment. *P < 0.05.

Back to article page